Clinical Trials
405
Active:19
Completed:197
Trial Phases
6 Phases
Early Phase 1:12
Phase 1:130
Phase 2:124
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (393 trials with phase data)β’ Click on a phase to view related trials
Phase 1
130 (33.1%)Phase 2
124 (31.6%)Not Applicable
120 (30.5%)Early Phase 1
12 (3.1%)Phase 3
5 (1.3%)Phase 4
2 (0.5%)Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas
Not Applicable
Not yet recruiting
- Conditions
- Basal Cell Carcinoma
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT07182240
- Locations
- πΊπΈ
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)
Not Applicable
Recruiting
- Conditions
- Cigarette Smoking-Related Carcinoma
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 150
- Registration Number
- NCT07167225
- Locations
- πΊπΈ
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Influence of Authorized Smokeless Tobacco Product Modified Risk Claims II: Laboratory Assessment of Sensory and Subjective Effects
Not Applicable
Recruiting
- Conditions
- Smokeless Tobacco
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT07107139
- Locations
- πΊπΈ
Roswell Park, Buffalo, New York, United States
Influence of Authorized Smokeless Tobacco Product Modified Risk Claims I: Consumer Product Demand
Not Applicable
Recruiting
- Conditions
- Smoking Behaviors
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 160
- Registration Number
- NCT07102082
- Locations
- πΊπΈ
Roswell Park, Buffalo, New York, United States
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Not Applicable
Not yet recruiting
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyOther: Questionnaire Administration
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT07082270
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 81
- Next
News
No news found